A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Trial Profile

A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Derazantinib (Primary)
  • Indications Cholangiocarcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 21 Nov 2017 According to an ArQule media release, the company announced dosing of the initial four patients in this trial.
    • 09 Nov 2017 According to an ArQule media release, an interim analysis will be preformed after the first 40 patients have been enrolled and evaluated for response.
    • 16 Oct 2017 According to an ArQule media release, company anticipates to complete enrollment of patients needed to perform the interim analysis through the first part of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top